Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030 owing to the rising need for biodefense agents and equipment in the region. The rise in naturally occurring outbreaks, the threat posed by biological weapons, and the development of ICBMs with nuclear warheads are the main reasons why the biodefense market is expanding. Restrictive constraints, such as financial swings brought on by a changing EU, are anticipated to hinder market expansion in the years to come. The growth of biopharmaceuticals contract manufacturing is also anticipated to increase throughout the forecast period due to the rising implementation of technology and predictive analytics to redefine the biodefense market. The government spends a lot of money each year on vaccine research and development in order to be ready for potential bioterrorism threats. The UK government, for instance, published several documents in 2018: the Biological Security Strategy, Strategic Defense and Security Review, Global Health Security, UK Antimicrobial Resistance Strategy, National Counterterrorism Strategy, Counterterrorism Strategy CONTEST, National Counter-Proliferation Strategy to 2020, UK Influenza Preparedness Strategy, Strategy for UK Life Sciences, Vision, and High Level Strategy for UK Animal and Plant Health Research to 20. As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. The initiatives of governments worldwide open a window of opportunities for the firms involved in the biodefense sector. Thus, owing to the factors mentioned above are likely to boost the growth of the Biodefense Market in Europe during the forecast period. Following the trends in the Asia-Pacific region the European market also gave the majority of the share to the Anthrax segment. This segment accounted for the largest market share in the Biodefense Market in Europe. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioWeapons Prevention Project (BWPP), British American Security Information Council (BASIC), and the German Biosecurity Programme.


Covid-19 Impact
 
The global struggle to tackle the COVID-19 pandemic has exposed the vulnerability of global societies to natural and manmade biological threats, prompting experts to warn of a potential increase in the use of biological weapons, like viruses or bacteria, in a post-coronavirus world. As a result of this the European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. All of these factors along with the plan to be prepared for the future has driven investors with large sum of money to the European Biodefence market, providing its further growth in the future 


Highlighted with 35 tables and 41 figures, this 109-page report “Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain

In-depth qualitative analyses include identification and investigation of the following aspects:
   • Market Structure 
   • Growth Drivers 
   • Restraints and Challenges
   • Emerging Product Trends & Market Opportunities
   • Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country. 

By Product type  
     • Vaccines
            • Anthrax
            • Smallpox
            • Botulism
            • Nuclear/Radiation
            • E-Bola
            • Zika
            • Other Vaccines
     • Biothreat Detection Devices
            • Detectors/Triggering Devices
            • Assays and Reagents
            • Samplers
            • Identifiers
     •Antibiotics
     • Masks
     • Other Products 

By Sales Channel
     • Online Sales
     • Offline Sales

By Application
     • Military
     • Civilian

By Geography
     • Germany
     • UK
     • France
     • Spain
     • Italy
     • Russia
     • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation, 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Arun Kalwani

Arun Kalwani

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Arun Kalwani

Table of Contents

  • 1. Introduction
  • 1.1. Industry Definition and Research Scope
  • 1.1.1. Industry Definition
  • 1.1.2. Research Scope
  • 1.2. Research Methodology
  • 1.2.1. Overview of Market Research Methodology
  • 1.2.2. Market Assumption
  • 1.2.3. Secondary Data
  • 1.2.4. Primary Data
  • 1.2.5. Data Filtration and Model Design
  • 1.2.6. Market Size/Share Estimation
  • 1.2.7. Research Limitations
  • 1.3. Executive Summary
  • 2. Market Overview and Dynamics
  • 2.1. Market Size and Forecast
  • 2.2. Major Growth Drivers
  • 2.3. Market Restraints and Challenges
  • 2.4. Emerging Opportunities and Market Trends
  • 2.5. Porter’s Fiver Forces Analysis
  • 3. Segmentation of Europe Market by Product
  • 3.1. Market Overview by Product
  • 3.2. Vaccines
  • 3.2.1. Anthrax
  • 3.2.2. Smallpox
  • 3.2.3. Botulism
  • 3.2.4. Nuclear/Radiation
  • 3.2.5. E-Bola
  • 3.2.6. Zika
  • 3.2.7. Other Vaccines
  • 3.3. Biothreat Detection Devices
  • 3.4. Antibiotics
  • 3.5. Masks
  • 3.6. Other Products
  • 4. Segmentation of Europe Market by Sales Channel
  • 4.1. Market Overview by Sales Channel
  • 4.2. Online Sales
  • 4.3. Offline Sales
  • 5. Segmentation of Europe Market by Application
  • 5.1. Market Overview by Application
  • 5.2. Military
  • 5.3. Civilian
  • 6. Europe Market 2020-2030 by Country
  • 6.1. Overview of European Market
  • 6.2. Germany
  • 6.3. UK
  • 6.4. France
  • 6.5. Spain
  • 6.6. Italy
  • 6.7. Russia
  • 6.8. Rest of European Market
  • 7. Competitive Landscape
  • 7.1. Overview of Key Vendors
  • 7.2. New Product Launch, Partnership, Investment, and M&A
  • 7.3. Company Profiles
  • 7.3.1. Achaogen, Inc.
  • 7.3.2. Alexeter Technologies LLC
  • 7.3.3. Alnylam Pharmaceuticals, Inc.
  • 7.3.4. Altimmune, Inc.
  • 7.3.5. Bavarian Nordic AS
  • 7.3.6. BioFactura, Inc.
  • 7.3.7. Cleveland Biolabs, Inc.
  • 7.3.8. Dynavax Technologies Inc
  • 7.3.9. Dynport Vaccine Company LLC (DVC)
  • 7.3.10. Elusys Therapeutics, Inc.
  • 7.3.11. Emergent BioSolutions Inc
  • 7.3.12. General Dynamics Corp.
  • 7.3.13. GlaxoSmithKline Plc
  • 7.3.14. Ichor Medical Systems
  • 7.3.15. Mediimmune (AstraZeneca)
  • 7.3.16. Nanotherapeutics, Inc.
  • 7.3.17. Ology Bioscience
  • 7.3.18. PathSensors Inc
  • 7.3.19. Pluristem Therapeutics
  • 7.3.20. Sanofi Pasteur Ltd.
  • 7.3.21. SIGA Technologies, Inc.
  • 7.3.22. Soligenix, Inc.
  • 7.3.23. Xoma Corporation
  • 8. Investing in Europe Market: Risk Assessment and Management
  • 8.1. Risk Evaluation of Europe Market
  • 8.2. Critical Success Factors (CSFs)
  • Related Reports and Products

List of Tables

Table 1. Snapshot of Europe Biodefense Market, 2020-2030
Table 2. Main Product Trends and Market Opportunities in Europe Biodefense Market
Table 3. Europe Biodefense Market by Product, 2020-2030, $ mn
Table 4. Europe Biodefense Market: Vaccines by Application, 2020-2030, $ mn
Table 5. List of Biodefense Vaccine Pipelines
Table 6. Europe Biodefense Market: Vaccines Biothreat Detection Devices by Type, 2020-2030, $ mn
Table 7. Europe Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 8. Europe Market by Application, 2020-2030, $ mn
Table 9. Europe Biodefense Market by Country, 2020-2030, $ mn
Table 10. Germany Biodefense Market by Product, 2020-2030, $ mn
Table 11. Germany Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 12. Germany Biodefense Market by Application, 2020-2030, $ mn
Table 13. UK Biodefense Market by Product, 2020-2030, $ mn
Table 14. UK Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 15. UK Biodefense Market by Application, 2020-2030, $ mn
Table 16. France Biodefense Market by Product, 2020-2030, $ mn
Table 17. France Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 18. France Biodefense Market by Application, 2020-2030, $ mn
Table 19. Spain Biodefense Market by Product, 2020-2030, $ mn
Table 20. Spain Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 21. Spain Biodefense Market by Application, 2020-2030, $ mn
Table 22. Italy Biodefense Market by Product, 2020-2030, $ mn
Table 23. Italy Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 24. Italy Biodefense Market by Application, 2020-2030, $ mn
Table 25. Russia Biodefense Market by Product, 2020-2030, $ mn
Table 26. Russia Biodefense Market by Sales Channel, 2020-2030, $ mn
Table 27. Russia Biodefense Market by Application, 2020-2030, $ mn
Table 28. Biodefense Market in Rest of Europe by Country, 2020-2030, $ mn
Table 29. Achaogen, Inc.: Company Snapshot
Table 30. Achaogen, Inc.: Business Segmentation
Table 31. Achaogen, Inc.: Product Portfolio
Table 32. Achaogen, Inc.: Revenue, 2019-2021, $ mn
Table 33. Achaogen, Inc.: Recent Developments
Table 34. Risk Evaluation for Investing in Europe Market, 2020-2030
Table 35. Critical Success Factors and Key Takeaways

List of Figures

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2030
Figure 5. Europe Biodefense Market, 2020-2030, $ mn
Figure 6. Primary Drivers and Impact Factors of Europe Biodefense Market
Figure 7. Primary Restraints and Impact Factors of Europe Biodefense Market
Figure 8. Investment Opportunity Analysis
Figure 9. Porter’s Fiver Forces Analysis of Europe Biodefense Market
Figure 10. Breakdown of Europe Biodefense Market by Product, 2020-2030, % of Sales Revenue
Figure 11. Europe Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%)
Figure 12. Europe Biodefense Market: Vaccines, 2020-2030, $ mn
Figure 13. Europe Biodefense Market: Anthrax, 2020-2030, $ mn
Figure 14. Europe Biodefense Market: Smallpox, 2020-2030, $ mn
Figure 15. Europe Biodefense Market: Botulism, 2020-2030, $ mn
Figure 16. Europe Biodefense Market: Nuclear/Radiation, 2020-2030, $ mn
Figure 17. Europe Biodefense Market: E-Bola, 2020-2030, $ mn
Figure 18. Europe Biodefense Market: Zika, 2020-2030, $ mn
Figure 19. Europe Biodefense Market: Other Vaccines, 2020-2030, $ mn
Figure 20. Europe Biodefense Market: Biothreat Detection Devices, 2020-2030, $ mn
Figure 21. Europe Biodefense Market: Antibiotics, 2020-2030, $ mn
Figure 22. Europe Biodefense Market: Masks, 2020-2030, $ mn
Figure 23. Europe Biodefense Market: Other Products, 2020-2030, $ mn
Figure 24. Breakdown of Europe Biodefense Market by Sales Channel, 2020-2030, % of Sales Revenue
Figure 25. Europe Addressable Market Cap in 2020-2030 by Sales Channel, Value ($ mn) and Share (%)
Figure 26. Europe Biodefense Market: Online Sales, 2020-2030, $ mn
Figure 27. Europe Biodefense Market: Offline Sales, 2020-2030, $ mn
Figure 28. Breakdown of Europe Market by Application, 2020-2030, % of Revenue
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Europe Biodefense Market: Military, 2020-2030, $ mn
Figure 31. Europe Biodefense Market: Civilian, 2020-2030, $ mn
Figure 32. Breakdown of European Biodefense Market by Country, 2020 and 2030, % of Revenue
Figure 33. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 34. Biodefense Market in Germany, 2020-2030, $ mn
Figure 35. Biodefense Market in UK, 2020-2030, $ mn
Figure 36. Biodefense Market in France, 2020-2030, $ mn
Figure 37. Biodefense Market in Spain, 2020-2030, $ mn
Figure 38. Biodefense Market in Italy, 2020-2030, $ mn
Figure 39. Biodefense Market in Russia, 2020-2030, $ mn
Figure 40. Biodefense Market in Rest of Europe, 2020-2030, $ mn
Figure 41. Growth Stage of Europe Biodefense Industry over the Forecast Period

Why Bonafide Research?

  • Our seasoned industry experts bring diverse sector experience, tailoring methodologies to your unique challenges.
  • Leveraging advanced technology and time-tested methods ensures accurate and forward-thinking insights.
  • Operating globally with a local touch, our research spans borders for a comprehensive view of international markets.
  • Timely and actionable insights empower swift, informed decision-making in dynamic market landscapes.
  • We foster strong client relationships based on trust, transparency, and collaboration.
  • Our dedicated team adapts and evolves strategies to meet your evolving needs.
  • Upholding the highest standards of ethics and data security, we ensure confidentiality and integrity throughout the research process.

How client has rates us?

Requirement Gathering & Methodology
92%
Data Collection Techniques
97%
Our Research Team & Data Sourcing
93%
Data Science & Analytical Tools
81%
Data Visualization & Presentation Skills
86%
Project/ Report Delivery & After Sales Services
88%
Logo

Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

We are friendly and approachable, give us a call.